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Angiotensin-Converting Enzyme Inhibition and Angiotensin
II Type 1 Receptor Blockade Prevent Cardiac Remodeling
in Pigs After Myocardial Infarction
Role of Tissue Angiotensin II
Jorge P. van Kats, PhD; Dirk J. Duncker, MD, PhD; David B. Haitsma, MD; Martin P. Schuijt, MSc;
Remko Niebuur, MSc; Rene´ Stubenitsky, MSc; Frans Boomsma, PhD;
Maarten A.D.H. Schalekamp, MD, PhD; Pieter D. Verdouw, PhD; A.H. Jan Danser, PhD
Background—The mechanisms behind the beneficial effects of renin-angiotensin system blockade after myocardial
infarction (MI) are not fully elucidated but may include interference with tissue angiotensin II (Ang II).
Methods and Results—Forty-nine pigs underwent coronary artery ligation or sham operation and were studied up to 6
weeks. To determine coronary angiotensin I (Ang I) to Ang II conversion and to distinguish plasma-derived Ang II from
locally synthesized Ang II, 125I-labeled and endogenous Ang I and II were measured in plasma and in infarcted and
noninfarcted left ventricle (LV) during 125I-Ang I infusion. Ang II type 1 (AT1) receptor–mediated uptake of circulating
125I-Ang II was increased at 1 and 3 weeks in noninfarcted LV, and this uptake was the main cause of the transient
elevation in Ang II levels in the noninfarcted LV at 1 week. Ang II levels and AT1 receptor–mediated uptake of
circulating Ang II were reduced in the infarct area at all time points. Coronary Ang I to Ang II conversion was
unaffected by MI. Captopril and the AT1 receptor antagonist eprosartan attenuated postinfarct remodeling, although both
drugs increased cardiac Ang II production. Captopril blocked coronary conversion by .80% and normalized Ang II
uptake in the noninfarcted LV. Eprosartan did not affect coronary conversion and blocked cardiac Ang II uptake by
.90%.
Conclusions—Both circulating and locally generated Ang II contribute to remodeling after MI. The rise in tissue Ang II
production during angiotensin-converting enzyme inhibition and AT1 receptor blockade suggests that the antihypertro-
phic effects of these drugs result not only from diminished AT1 receptor stimulation but also from increased stimulation
of growth-inhibitory Ang II type 2 receptors. (Circulation. 2000;102:1556-1563.)
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Angiotensin-converting enzyme (ACE) inhibitors preventcardiac remodeling (ie, ventricular hypertrophy and
chamber dilatation) after myocardial infarction (MI). This
occurs, in part, independent of their blood pressure–lowering
effect,1 suggesting interference with tissue angiotensin II
(Ang II). However, ACE inhibitors do not always lower
cardiac Ang II2–4 because of (1) their pharmacokinetic
properties (short half-life and lack of tissue penetration),3,4 (2)
ACE upregulation during prolonged ACE inhibition,5 or (3)
alternative converting enzymes, such as chymase.6 Further-
more, previous Ang II measurements in infarcted hearts4,7,8
have not taken into account the fact that cardiac Ang II is
partly derived from the circulation. Plasma Ang II accumu-
lates in the heart through Ang II type 1 (AT1) receptor–
mediated endocytosis,2,9 and changes in AT1 receptor density
after MI10,11 may influence this process.
AT1 receptor antagonists have opened new avenues in the
investigation of the importance of cardiac Ang II after MI. In
general, these drugs increase rather than decrease Ang II
levels,12 and this may lead to activation of unoccupied
growth-inhibitory13 Ang II type 2 (AT2) receptors. Currently,
the effect of AT1 receptor antagonism on the Ang II content
of the infarcted heart is unknown. Furthermore, it is still
controversial whether AT1 receptor antagonism prevents the
development of cardiac hypertrophy and increases survival
after MI.14,15
Therefore, the aim of the present study was to investigate
changes in cardiac Ang II content and origin (local synthesis
versus uptake from plasma) after MI in pigs, to compare the
effects of ACE inhibition and AT1 receptor antagonism on
these changes, and to evaluate whether the effects of both
renin-angiotensin system (RAS) blockers on cardiac angio-
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tensin content are related to their effects on postinfarct
remodeling.
Methods
Animals
Experiments were performed in accordance with the Guide for the
Care and Use of Laboratory Animals (NIH Publication 86-23,
revised 1985). Forty-nine 2- to 3-month-old Yorkshire3Landrace
pigs of either sex entered the study. Adaptation of animals to
laboratory conditions started 1 week before surgery.
Surgical Procedure
Animals were sedated with ketamine (30 mg/kg IM), anesthetized
with thiopental (10 mg/kg IV), intubated, and ventilated with a
mixture of O2 and N2O, to which 0.2% to 1.0% (vol/vol) isoflurane
was added.16 Anesthesia was maintained with midazolam (2 mg/
kg11 mg/kg per hour IV) and fentanyl (10 mg/kg per hour IV). The
chest was opened via a left intercostal space, and a fluid-filled
polyvinylchloride catheter was inserted into the aortic arch for
hemodynamic monitoring and blood sampling.16 Subsequently, the
pericardium was opened, the proximal left circumflex coronary
artery (LCXCA) was dissected out, and a suture was placed around
the LCXCA. In 35 animals, the LCXCA was permanently ligated
(MI group), whereas in 14 animals, the suture was removed (sham
group). The pericardium was closed, and the aortic catheter was
tunneled subcutaneously to the back. The chest was closed, and the
animals were allowed to recover. Animals received analgesia (0.3
mg buprenorphine IM) for 2 days and antibiotic prophylaxis (25
mg/kg amoxicillin and 5 mg/kg gentamycin IV) for 5 days.16
Experimental Groups
Animals were followed for 1, 3, or 6 weeks. Of the 3-week MI
animals, 6 received captopril (25 mg PO BID), and 7 received the
AT1 receptor antagonist eprosartan (400 mg PO BID, a gift of Dr
P.K. Weck, SmithKline Beecham, Collegeville, Pa). This dose of
eprosartan blocks Ang II–induced pressor responses by .95%
(n53). Treatment started 12 to 24 hours after LCXCA ligation and
was continued for 3 weeks.
Echocardiography
At the end of the follow-up period, animals were sedated with
ketamine, and 2D echocardiographic recordings of the left ventric-
ular (LV) short axis at midpapillary level were obtained (Sonos
5500, Hewlett-Packard) and stored for offline analysis. LV end-di-
astolic cross-sectional area (EDA) and end-systolic cross-sectional
area (ESA) were determined, and ejection fraction (EF) was calcu-
lated as (EDA2ESA)/EDA3100%.
Infusion of 125I-Ang I
After echocardiography, pigs were anesthetized and prepared for
hemodynamic monitoring, administration of 125I-angiotensin I (Ang
I), and blood and tissue sampling.9,17 After baseline measurements
were collected, the animals were subjected to a 60-minute infusion of
125I-Ang I (’43106 cpm/min) into the LV cavity. 125I-Ang I and
125I-Ang II reach steady-state levels in plasma and cardiac tissue
within 10 and 60 minutes, respectively.9
Blood and Tissue Sampling
During follow-up, arterial blood samples were collected in the
morning from awake animals for measurement of norepinephrine,
epinephrine, atrial natriuretic peptide (ANP), N-terminal ANP, Ang
I, and Ang II.2,18,19 During 125I-Ang I infusion, arterial and coronary
venous blood samples were collected from anesthetized animals for
measurement of endogenous and 125I-labeled Ang I and II.2,9 With
the 125I-Ang I infusion still running, the heart was stopped by
fibrillation, the LV and right ventricle (RV) were separated and
weighed, and 0.5- to 1-g samples were rapidly obtained from
noninfarcted anterior LV wall, lateral LV wall (containing the infarct
area and border zone after MI), interventricular septum, and RV
wall. Samples were immediately frozen in liquid nitrogen and stored
at 270°C.
Biochemical Measurements
Norepinephrine, epinephrine, ANP, and N-terminal ANP were mea-
sured as described before.18,19 Endogenous and 125I-labeled Ang I and
II were measured, after SepPak extraction and high-performance
liquid chromatography separation, by g counting and radioimmuno-
assay, respectively.2,9
Data Analysis
Fractional conversion and degradation of 125I-Ang I in the coronary
vascular bed, ie, the percentage of arterially delivered 125I-Ang I that
is converted to 125I-Ang II or degraded to other angiotensin metab-
olites during coronary passage, were calculated as described previ-
ously.20 To quantify cardiac Ang I and II synthesis, tissue levels of
Ang I and II were corrected for uptake from plasma by using the
steady-state plasma and tissue levels of 125I-Ang I and II.2 Cardiac
tissue 125I-Ang I was undetectable in nearly all animals. To prevent
underestimation of the contribution of plasma Ang I to tissue Ang I,
in situ–synthesized tissue Ang I was quantified under the assumption
that tissue 125I-Ang I equals 5% of the steady-state plasma levels of
125I-Ang I.2 Differences between sham and MI animals and differ-
ences between treated and untreated animals were tested by 2-way
ANOVA or multivariate ANOVA, followed by the Student t test.
Statistical significance was accepted at P,0.05. Data are expressed
as mean6SEM.
Results
Mortality
All sham animals survived the follow-up period, but 2 sham
animals died during 125I-Ang I infusion because of technical
failure. Eight MI animals died within 12 hours after induction of
MI, and 2 died during eprosartan treatment on days 7 and 15.
Hemodynamic and Neurohumoral Characteristics
One day after surgery, mean arterial pressure was lower and
heart rate was higher in MI pigs than in sham pigs (Figure 1).
Mean arterial pressure partially recovered in the MI group
during the first week but remained below sham levels during
follow-up. Plasma norepinephrine and epinephrine levels
were similar in MI and sham animals, whereas plasma ANP
and N-terminal ANP were higher in MI animals during the
entire follow-up period. Captopril and eprosartan did not
affect any of the hemodynamic or neurohumoral parameters
(data not shown).
Remodeling
LV EDA and ESA were increased at 1 week after MI, so that
EF was lower in MI animals (Table 1). EF recovered during
the follow-up period, although LV EDA and ESA remained
increased compared with sham values. Captopril and epro-
sartan blunted the increases in LV dimension, thereby slightly
increasing EF.
After MI, the surviving myocardium hypertrophied, as
reflected by the increased LV and RV weights and the ratios
of LV and RV weight to body weight (Table 1). Captopril and
eprosartan attenuated LV and RV hypertrophy.
Hemodynamics During Anesthesia
Hemodynamics did not differ between MI and sham animals,
except for LV end-diastolic pressure and pulmonary arterial
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pressure, which were higher (P,0.05) in MI pigs at 3 weeks
(Table 1). Neither captopril nor eprosartan affected
hemodynamics.
Angiotensin Levels in Plasma
In animals in the awake state, plasma Ang I and II levels
(Figure 1) were somewhat higher than those levels in anes-
thetized animals (Table 2). However, the changes produced
by MI and RAS blockade in animals in the awake state
paralleled those in anesthetized animals. The Ang I and II
levels in arterial and coronary venous plasma in MI animals
were marginally higher (P5NS) than those in corresponding
sham animals at 1 week. At 3 and 6 weeks, the levels were
similar in both groups. Captopril increased plasma Ang I 5- to
10-fold but did not alter plasma Ang II in MI animals. The
plasma Ang II/Ang I ratio decreased by ’80% during
captopril treatment, indicating effective ACE inhibition.
Eprosartan increased plasma Ang I and II in MI animals 5- to
10-fold, without altering the plasma Ang II/Ang I ratio.
Neither the steady-state 125I-Ang I and II levels nor the
125I-Ang II/Ang I ratios in arterial and coronary venous
plasma differed between sham and MI animals at any time
point. Captopril reduced the 125I-Ang II levels and the 125I-Ang
II/Ang I ratio at both sampling sites, whereas eprosartan did
not alter the steady-state plasma 125I-Ang I and II levels.
Ang I Metabolism in Coronary Vascular Bed
Coronary 125I-Ang I–Ang II conversion and 125I-Ang I degra-
dation in sham animals (Table 2) were not different from
those reported in noninstrumented normal pigs.20 MI did not
alter Ang I conversion or degradation at any time point.
Captopril inhibited conversion but did not affect degradation.
Eprosartan affected neither conversion nor degradation.
Angiotensin Levels in Tissue
Ang I and II levels in the noninfarcted myocardium were
higher in MI animals than in sham animals at 1 week but not
at 3 and 6 weeks (Figures 2 and 3). In sham animals, Ang II
levels were similar at all myocardial sites, whereas in MI
animals, Ang II levels were lowest in the center of the infarct
region and intermediate in the border zone. Both captopril
Figure 1. Mean arterial blood pressure, heart rate, and arterial
plasma levels of neurohormones in sham (E) and MI (F) ani-
mals. N-atrial natriuretic peptide indicates N-terminal atrial natri-
uretic peptide. *P,0.05 vs sham.
TABLE 1. Hemodynamics and Morphology
Parameter
1 wk 3 wk 6 wk
Sham
(n54)
MI
(n54)
Sham
(n55)
MI
(n56)
MI1Captopril
(n56)
MI1Eprosartan
(n55)
Sham
(n53)
MI
(n54)
MAP, mm Hg 9564 9063 9364 9666 8564 8962 9466 10063
Heart rate, bpm 11565 124611 10166 10368 10365 11368 11869 13068
Cardiac output, L/min 2.260.1 1.960.2 3.060.2 2.760.1 2.860.3 2.260.3 2.860.2 3.560.2
LV dP/dtmax, mm Hg/s 23436214 22216301 20536138 1706678 18726162 16906127 19406104 2053699
LVEDP, mm Hg 762 1062 862 1462* 1161 1163 761 962
PAP, mm Hg 2164 3161 1663 2862* 2564 2463 2365 3163
EDA, cm2 8.160.1 13.660.3* 9.761.4 12.861.5 11.861.2 11.660.7 10.060.3 15.864.2
ESA, cm2 4.160.5 10.460.6* 4.660.8 8.661.6* 6.961.0 7.061.3 5.760.8 9.762.8
EF, % 5066 2463* 5364 3369* 4263* 4268 4366 4064
BW, kg 23.760.5 23.561.2 30.061.4 28.761.1 28.361.4 28.460.6 36.561.5 40.161.5
LVW, g 75.161.4 90.661.1* 82.766.2 102.265.2* 88.263.2† 82.564.4† 102.161.0 131.3612.2*
RVW, g 30.762.7 32.562.8 27.361.0 40.163.1* 31.961.5*† 30.362.7† 27.862.5 52.964.7*
LVW/BW, g/kg 3.1760.11 3.9060.22* 2.7560.16 3.5760.14* 3.1760.25† 2.9160.16† 2.8060.09 3.3260.42
RVW/BW, g/kg 1.3060.10 1.3960.12 0.9160.04 1.3960.06* 1.1460.06*† 1.0660.08† 0.7760.10 1.3460.16*
Values are mean6SEM. MAP indicates mean arterial pressure; LVEDP, LV end-diastolic pressure; PAP, pulmonary arterial pressure; BW, body weight; LVW, LV
weight; and RVW, RV weight.
*P,0.05 vs sham; †P ,0.05 vs untreated MI.
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and eprosartan increased Ang I and II 2- to 3-fold at all tissue
sites in MI animals (Figures 2 and 3), without altering the
tissue Ang II/Ang I ratios significantly (data not shown).
125I-Ang I was undetectable in all regions, indicating that
virtually all tissue Ang I had been produced in situ (Figure 2).
125I-Ang II accumulated in cardiac tissue, reaching steady-
state levels in the noninfarcted myocardium that were com-
parable to or higher than those in arterial plasma (Figure 4).
125I-Ang II levels in the infarcted and border-zone lateral LV
wall were ’20% to 30% and ’60% to 70% of those in
arterial plasma. Blockade of cardiac 125I-Ang II accumulation
by eprosartan (Figure 4) indicates that this process is AT1
receptor–mediated. There were no changes in 125I-Ang II
accumulation in the RV wall or in the infarcted or border-
zone lateral LV wall during the follow-up period. In sham
animals compared with normal noninstrumented animals,
125I-Ang II accumulation in the noninfarcted anterior LV wall
and the interventricular septum was increased at 1 week but
not at 3 and 6 weeks,9 whereas it was elevated in MI animals
at 1 week and 3 weeks but not at 6 weeks. Captopril abolished
the increased 125I-Ang II accumulation in the noninfarcted
myocardium of MI animals at 3 weeks. After the tissue
125I-Ang II levels were used to correct for uptake of circulat-
ing Ang II, it appeared that the increase in cardiac Ang II
levels in MI animals at 1 week was mainly due to uptake from
plasma, whereas the increases in cardiac Ang II levels in
captopril- and eprosartan-treated animals were due to Ang II
generated in situ from locally synthesized Ang I (Figure 3).
Discussion
The present study demonstrates that after MI, the Ang II
levels in the noninfarcted LV are transiently increased be-
cause of enhanced AT1 receptor–mediated uptake of circulat-
ing Ang II. Captopril and eprosartan normalized or blocked
this uptake and attenuated postinfarct remodeling but in-
creased local cardiac Ang II production. These results suggest
that the antihypertrophic effects of RAS blockade result not
only from diminished AT1 receptor stimulation but also from
increased stimulation of growth-inhibitory AT2 receptors.
LCXCA ligation caused LV and RV hypertrophy within 1
to 3 weeks. MI was accompanied by a transient but severe
decrease in mean arterial pressure, which, via stimulation of
renal renin release, may have caused the modest (nonsignif-
icant) rise in plasma angiotensin levels in the first week. The
hemodynamic and neurohumoral profile of the MI animals
indicates that permanent LCXCA occlusion, which results in
15% to 25% infarction of the porcine LV, was associated with
mild-to-moderate LV dysfunction, requiring minimal sympa-
thetic activation to maintain cardiovascular homeostasis. This
contrasts with an atrial pacing model in pigs, which led to
severe heart failure and significant neurohumoral activation
within 3 weeks.21 Interestingly, in the latter model, LV AT1
receptor density was decreased, whereas after MI, LV AT1
receptors are usually upregulated.10,22 The present findings
are in agreement with such upregulation, inasmuch as the
amount of plasma-derived 125I-Ang II sequestered by the
noninfarcted LV myocardium via AT1 receptor–mediated
internalization at 1 week and 3 weeks after MI was twice as
high as that in a previous study in normal pigs.9 However,
similar increases were observed in sham animals at 1 week
after surgery, suggesting that this procedure, possibly through
the induction of a fibrogenic response,22 is partly responsible
for the increase in AT1 receptor density. It must be realized
that 125I-Ang II uptake in the heart is mediated exclusively via
TABLE 2. Plasma Angiotensin Levels, Ang II/Ang I Ratios, and Coronary Ang I Metabolism
Parameter
1 wk 3 wk 6 wk
Sham
(n54)
MI
(n54)
Sham
(n55)
MI
(n56)
MI1Captopril
(n56)
MI1Eprosartan
(n55)
Sham
(n53)
MI
(n54)
Aorta
Ang I, pmol/L 4.561.7 8.464.3 4.961.6 2.961.0 24.768.5*† 19.064.7*† 2.160.3 3.061.0
Ang II, pmol/L 1.460.1 6.662.9 3.661.2 1.960.5 4.261.6 16.563.4*† 1.160.1 2.160.7
Ang II/I ratio 0.5460.22 0.8260.08 0.6260.08 0.7360.04 0.1660.05*† 0.9260.09 0.5060.12 0.4960.20
125I-Ang I, 103 cpm/L 546676 501652 420628 5456106 620663 563673 369628 459650
125I-Ang II, 103 cpm/L 263619 255633 232646 286662 100615*† 385615 186612 352681
125I-Ang II/I ratio 0.5060.05 0.5160.05 0.5660.12 0.5760.14 0.1760.03*† 0.7360.09 0.5160.01 0.7460.13
Coronary vein
Ang I, pmol/L 2.660.8 7.163.2 4.761.1 2.561.0 21.867.6*† 15.863.9*† 1.960.3 3.160.8
Ang II, pmol/L 1.160.2 4.862.0 2.860.8 1.460.3 4.561.4 18.063.2*† 1.360.2 1.960.6
Ang II/I ratio 0.5860.22 0.6360.08 0.4960.08 0.6660.10 0.1860.06*† 0.9660.16 0.6560.25 0.5960.13
125I-Ang I, 103 cpm/L 257635 323635 203631 267674 455650 225628 193625 250626
125I-Ang II, 103 cpm/L 277623 268638 223648 289652 97611*† 346616 223633 349658
125I-Ang II/I ratio 1.1260.08 0.8260.05 1.1460.16 1.2260.20 0.2160.04*† 1.6760.26 1.1760.17 1.2160.17
Coronary 125I-Ang I metabolism
Fractional conversion, % 2461 1761 2064 2562 461*† 2664 2664 2461
Fractional degradation, % 2962 2064 3166 3164 2361 3165 2264 2262
Values are mean6SEM.
*P,0.05 vs sham; †P,0.05 vs untreated MI.
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AT1 receptors, because AT2 receptors do not internalize Ang
II.9,23 Furthermore, 125I-Ang II formation from 125I-Ang I that
has diffused into the interstitial space does not contribute
significantly to the steady-state tissue levels of 125I-Ang II.9,24
The increase in AT1 receptor–mediated uptake of circulat-
ing Ang II is responsible for the transient rise in Ang II levels
in the noninfarcted LV myocardium, suggesting that circulat-
ing Ang II is among the factors initiating the development of
LV hypertrophy, even when plasma Ang II is only marginally
increased. This observation extends previous studies demon-
strating that elevation of circulating Ang II, either through
infusion of Ang II or through renovascular hypertension,
induces biventricular hypertrophy within 2 weeks.25 In-
creased 125I-Ang II levels in the noninfarcted LV myocardium
were no longer observed at 6 weeks, nor were they present in
captopril-treated animals at 3 weeks. This, in combination
with the notion that eprosartan fully blocked the uptake of
circulating 125I-Ang II at all myocardial locations, suggests
that RAS blockade prevents the development of LV hyper-
trophy, at least in part, by attenuating or blocking the AT1
receptor–mediated uptake of circulating Ang II.
In addition to their effects on cardiac 125I-Ang II uptake,
both captopril and eprosartan increased plasma and cardiac
Ang I. Because cardiac renin is derived from the circulation,
both under normal circumstances and after MI,26–28 these
increases most likely reflect the rise in renal renin release that
normally accompanies RAS blockade. It is currently un-
known whether enzymes other than renin (eg, cathepsin D29)
contribute to Ang I generation in infarcted hearts. Similarly,
the origin of cardiac angiotensinogen after MI has not been
fully elucidated, although recent data suggest that most
angiotensinogen in infarcted hearts,27 as in normal hearts,26 is
plasma-derived.
In the eprosartan-treated pigs, plasma and cardiac Ang II
rose in parallel with Ang I, whereas in the captopril-treated
pigs, Ang II did not change in the circulation but increased in
the heart. Consequently, the Ang II/Ang I ratio, a measure of
ACE activity, was decreased in plasma but not in the heart
after captopril treatment.
The rise in cardiac Ang II synthesis with captopril may
have several causes. First, captopril may not have entered the
heart in sufficient quantities. This seems unlikely, because in
an earlier study, we observed a clear reduction in the cardiac
Ang II/Ang I ratio after 3 days of treatment with the same
dose of captopril.2 It is also unlikely in view of the favorable
cardiac effects of captopril in humans after MI.1 Second,
cardiac Ang II synthesis might occur at intracellular sites24
that cannot be reached by ACE inhibitors. Third, the initial
captopril-induced blockade of cardiac tissue Ang I–Ang II
conversion2 may have been compensated for during long-
Figure 2. Cardiac Ang I levels. Black area in each bar represents amount of locally synthesized Ang I. *P,0.05 vs sham; †P,0.05 vs
untreated MI.
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term treatment with this drug, either through an upregulation
of ACE5 or because alternative converting enzymes such as
chymase6 have come into play. Our findings do not provide
evidence for changes in cardiac or coronary ACE activity,
because neither the cardiac Ang II/Ang I ratio nor coronary
Ang I–Ang II conversion was altered in MI animals. Al-
though MI-induced ACE upregulation has been de-
scribed,22,30 transgenic rats overexpressing cardiac ACE 40-
fold have normal cardiac Ang II levels.31 Moreover, we failed
to observe ACE gene insertion/deletion polymorphism–re-
lated differences in vascular Ang I–Ang II conversion despite
profound effects of this polymorphism on plasma and tissue
ACE levels.32 Thus, elevated cardiac ACE levels, if present in
MI pigs, do not necessarily result in elevated Ang II levels or
Ang II/Ang I ratios but may explain why captopril decreases
the cardiac Ang II/Ang I ratio less effectively. Furthermore,
chymase is present in the porcine heart,33 and its concentra-
tion increases after MI.34
Does the rise in cardiac Ang II production during RAS
blockade have a physiological function? If caused by chy-
mase, one must realize that chymase is present in the cytosol
of mast cells and in the extracellular matrix,6 whereas ACE is
located on the cell membrane, in proximity to AT1 recep-
tors.22,35 Consequently, Ang II generated by chymase may
couple less efficiently to AT1 receptors than Ang II generated
by ACE.36
AT2 receptor antagonism abolishes the beneficial effects of
AT1 receptor blockade in MI rats.37 This raises the possibility
that the rise in Ang II in the present study results in
stimulation of growth-inhibitory AT2 receptors.13,23 The AT2
receptor density is increased in infarcted and failing
hearts,10,11 and because the net effect of Ang II depends on
the AT1/AT2 receptor ratio,13 it is indeed conceivable that
growth inhibition occurs not only during AT1 receptor antag-
onism but also during ACE inhibition, because the latter
prevents the rise in AT1 receptor density after MI (the present
study) and is possibly accompanied by chymase-dependent
Ang I–Ang II conversion at sites distant from AT1
receptors.35,36
Enhanced AT2 receptor stimulation, together with dimin-
ished AT1 receptor stimulation, might also explain why
captopril and eprosartan prevented RV hypertrophy in MI
animals. Both drugs minimally affected the increase in
pulmonary arterial pressure that, in combination with the
elevated RV Ang II levels at 1 week after MI, may have
contributed to this hypertrophy.
Interestingly, the lowest 125I-Ang II accumulation and local
Ang II production were observed in the infarct area. The latter
finding could indicate that in this area, possibly secondary to
the reduced blood flow, renin uptake was diminished in
parallel with the diminished 125I-Ang II uptake. Alternatively,
and perhaps more likely in view of the unaltered local Ang I
Figure 3. Cardiac Ang II levels. Black area in each bar represents amount of locally synthesized Ang II. *P,0.05 vs sham; †P,0.05 vs
untreated MI.
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production in this area, the low 125I-Ang II and Ang II levels
might be the consequence of increased local Ang II
degradation.
In summary, MI results in a transient upregulation of AT1
receptors in spared noninfarcted myocardium, which will
cause enhanced sequestration of plasma Ang II even in the
absence of changes in the circulating RAS. RAS inhibitors
prevent the rise in plasma Ang II sequestration, either by
interfering with myocardial AT1 receptor upregulation or by
blocking these receptors. Furthermore, these inhibitors in-
crease tissue Ang II production, which through stimulation of
cardiac AT2 receptors may minimize postinfarct remodeling.
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